微电生理(688351) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥92,501,545.11, a decrease of 1.54% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 reached ¥24,713,982.12, an increase of 163.92% year-on-year[1] - The basic earnings per share for Q3 2024 was ¥0.0525, reflecting a growth of 163.82% compared to the same period last year[1] - Total revenue for the first three quarters of 2024 reached CNY 290,866,132.55, an increase from CNY 236,071,421.62 in the same period of 2023, representing a growth of approximately 23.2%[15] - Operating profit for the first three quarters of 2024 was CNY 43,955,481.15, significantly higher than CNY 13,519,615.21 in 2023, reflecting a growth of approximately 224.5%[18] - Net profit for the first three quarters of 2024 was CNY 41,726,652.80, compared to a net profit of CNY 11,519,616.22 in 2023, showing an increase of around 262.5%[18] - The total comprehensive income for Q3 2024 is CNY 41,727,175.52, compared to CNY 11,519,616.22 in Q3 2023, reflecting an increase of approximately 262%[19] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥1,868,108,151.72, representing a 2.46% increase from the end of the previous year[2] - The total assets as of the end of the reporting period were CNY 1,868,108,151.72, up from CNY 1,823,268,386.10 in the previous year, indicating an increase of approximately 2.5%[14] - Total liabilities were CNY 137,384,776.14, slightly down from CNY 138,210,343.16 in the previous year, reflecting a decrease of about 0.6%[14] - The company's equity attributable to shareholders increased to CNY 1,730,723,375.58 from CNY 1,685,058,042.94, marking an increase of approximately 2.7%[14] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥61,974,639.95[1] - The net cash flow from operating activities increased, primarily driven by the growth in operating profit[6] - Cash flow from operating activities for the first three quarters of 2024 is CNY 61,974,639.95, a significant improvement from a net cash outflow of CNY 40,741,045.35 in the same period of 2023[21] - The cash outflow for operating activities in the first three quarters of 2024 is CNY 302,621,144.71, slightly higher than CNY 297,463,858.79 in the same period of 2023[21] - The company's cash and cash equivalents as of September 30, 2024, were approximately RMB 232.79 million, down from RMB 265.53 million at the end of 2023[11] Research and Development - Research and development expenses totaled ¥21,472,078.06 in Q3 2024, a decrease of 30.69% year-on-year, accounting for 23.21% of operating revenue[2] - R&D investment decreased by 30.69% in the reporting period, as some projects entered the clinical late-stage, leading to reduced related expenditures[6] - Research and development expenses for the first three quarters of 2024 amounted to CNY 56,543,925.34, a decrease from CNY 64,194,405.61 in 2023, representing a reduction of about 11.8%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 6,718[6] - The largest shareholder, Ningbo Meishan Bonded Port Area Huajie Equity Investment Management Co., Ltd., holds 34.94% of shares[6] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[9] Government Subsidies and Other Income - Government subsidies recognized in Q3 2024 amounted to ¥21,050,527.20, contributing to profit growth[3] - The company reported a significant increase in other income, which rose to CNY 27,840,968.03 from CNY 9,909,622.00, representing a growth of approximately 180.5%[18]